![](/wp-content/uploads/2018/10/sP5FDKdTtWPa0dnsl26w.png)
$599
Zealand and Roche Partner for Ph3 stable glucagon development in CHI
Zealand has announced a collaboration with Roche for the Ph3 development of Zealand’s dasiglucagon for the treatment of congenital hyperinsulinism. Below, FENIX further analyzes this scenario.